Over the last seven days, the South Korean market has remained flat, though it has seen a 7.8% increase over the past year with earnings forecasted to grow by 29% annually. In this dynamic environment, identifying stocks that are poised for growth yet remain underappreciated can offer unique opportunities for investors seeking to capitalize on emerging trends.
Name
Debt To Equity
Revenue Growth
Earnings Growth
Health Rating
|
NOROO PAINT & COATINGS
|
13.99%
|
5.04%
|
7.74%
|
★★★★★★
|
|
Miwon Chemicals
|
0.08%
|
11.70%
|
14.38%
|
★★★★★★
|
|
Namuga
|
14.47%
|
0.88%
|
38.25%
|
★★★★★★
|
|
Synergy Innovation
|
12.39%
|
12.87%
|
28.82%
|
★★★★★★
|
|
ONEJOON
|
10.13%
|
35.30%
|
-5.78%
|
★★★★★☆
|
|
Oriental Precision & EngineeringLtd
|
54.53%
|
3.14%
|
0.80%
|
★★★★★☆
|
|
iMarketKorea
|
28.53%
|
5.35%
|
1.30%
|
★★★★★☆
|
|
Daewon Cable
|
30.50%
|
8.72%
|
60.28%
|
★★★★★☆
|
|
PaperCorea
|
53.09%
|
1.31%
|
77.27%
|
★★★★★☆
|
|
Itcen
|
64.57%
|
14.33%
|
-24.39%
|
★★★★★☆
|
Click here to see the full list of 180 stocks from our KRX Undiscovered Gems With Strong Fundamentals screener.
Below we spotlight a couple of our favorites from our exclusive screener.
Simply Wall St Value Rating: ★★★★★★
Overview: Boditech Med Inc. provides instruments and diagnostic reagents both in South Korea and internationally, with a market cap of ₩351.61 billion.
Operations: Boditech Med generates revenue primarily from diagnostic kits and equipment, amounting to ₩139.13 billion. The company’s market cap stands at ₩351.61 billion.
Boditech Med, a nimble player in South Korea’s medical equipment sector, has shown impressive earnings growth of 34.6% over the past year, outpacing the industry average of 4%. The company is trading at a significant discount, about 53.6% below its estimated fair value. Financially robust, Boditech holds more cash than total debt and has reduced its debt-to-equity ratio from 31.2% to 4.3% over five years. Recently announcing a KRW 3 billion share repurchase plan to enhance shareholder value, it seems poised for continued growth with forecasted earnings expansion of about 16.55% annually.
KOSDAQ:A206640 Earnings and Revenue Growth as at Oct 2024
Simply Wall St Value Rating: ★★★★★★
Overview: Hankook Shell Oil Co., Ltd. is involved in the manufacture, assembly, distribution, and marketing of lubricants, grease, and other petroleum-related products with a market cap of ₩417.95 billion.
Operations: Hankook Shell Oil Co., Ltd. generates revenue primarily from the sale of lubricants, grease, and petroleum-related products. The company’s financial performance is influenced by its cost structure and market demand for these products.
Story Continues
Hankook Shell Oil, a nimble player in South Korea’s oil and gas sector, has been making waves with its impressive financial health. The company boasts a 23.6% earnings growth over the past year, outpacing the industry average of -22.5%. Free from debt for five years, it eliminates concerns about interest coverage and showcases high-quality earnings. Recently added to the S&P Global BMI Index, Hankook Shell Oil trades at 17% below its estimated fair value, suggesting potential undervaluation. Its robust free cash flow further underscores financial stability amidst industry challenges.
KOSE:A002960 Earnings and Revenue Growth as at Oct 2024
Simply Wall St Value Rating: ★★★★★☆
Overview: NICE Information Service Co., Ltd. operates in South Korea offering credit evaluation, credit inquiries, credit investigations, and debt collection services with a market cap of approximately ₩663.84 billion.
Operations: NICE Information Service generates revenue primarily from corporate and personal credit information services, totaling ₩426.03 billion, and debt collection services, which contribute ₩68.44 billion.
NICE Information Service, a notable player in South Korea’s financial sector, has shown impressive performance with earnings growing 19.9% over the past year, outpacing the Professional Services industry. The company reported net income of ₩18.75 billion for Q2 2024, up from ₩16.81 billion last year, and basic earnings per share increased to ₩319 from ₩284. With a debt-to-equity ratio rising modestly to 0.4% over five years and trading at 68.2% below its estimated fair value, it seems well-positioned financially while maintaining high-quality earnings and positive free cash flow prospects.
KOSE:A030190 Earnings and Revenue Growth as at Oct 2024
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include KOSDAQ:A206640 KOSE:A002960 and KOSE:A030190.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
